BioVie (BIVI) vs Lexaria Bioscience (LEXX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BioVie is the larger company by market cap ($8.6 million vs $8.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIVI | LEXX |
|---|---|---|
| Share price | $0.80 | $4.03 |
| Market cap | $8.58M | $8.49M |
| 1-day change | -12.07% | -10.24% |
| YTD return | -31.03% | — |
| 1-year return | -38.22% | — |
| 5-year return | -99.87% | — |
| EPS (TTM) | $-2.85 | $-5.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $705.92K |
| Revenue growth (YoY) | — | +52.05% |
| Net income (latest FY) | $-22.07M | $-11.90M |
| Gross margin | — | 99.61% |
| Operating margin | — | -1683.01% |
| Net margin | — | -1686.00% |
| 52-week high | $3.79 | $21.60 |
| 52-week low | $0.7515 | $2.43 |
| Distance from 52-week high | -78.89% | -81.34% |
| Analyst consensus | none | none |
| Avg. price target upside | +557.50% | +1947.15% |
| Average volume | 568.61K | 70.52K |
| Shares outstanding | 10.72M | 2.11M |
| Employees | 13 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BioVie
BIVI stock →BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About Lexaria Bioscience
LEXX stock →Lexaria Bioscience Corp. operates as a biotechnology company.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
BIVI vs LEXX FAQ
Which is bigger, BioVie or Lexaria Bioscience?
BioVie (BIVI) is larger, with a market capitalization of $8.58M compared with $8.49M for Lexaria Bioscience (LEXX).
Are BioVie and Lexaria Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.